Ramipril
From Proteopedia
Line 1: | Line 1: | ||
- | <applet load="" size=" | + | <applet load="" size="430" color="" frame="true" spin="on" Scene ="Ramipril/Rama/1" align="right" caption="Ramiprilat, the metabolite of Ramipril, also known as Altace"/> |
===Better Known as: Altace or Ramipro=== | ===Better Known as: Altace or Ramipro=== | ||
* Marketed By: King Pharmaceuticals (Now part of Pfizer Inc.)<br /> | * Marketed By: King Pharmaceuticals (Now part of Pfizer Inc.)<br /> | ||
Line 14: | Line 14: | ||
===Pharmacokinetics=== | ===Pharmacokinetics=== | ||
- | + | <table style="background: cellspacing="0px" align="" cellpadding="0px" width="42%"> | |
- | + | <tr> | |
- | + | <td style="width:100%; vertical-align:top;border-width:0px; border-style:inset"> | |
- | + | <div style="height:100%; width: 100%"> | |
- | + | {{:ACE Inhibitor Pharmacokinetics}} | |
- | + | </div> | |
- | + | </td> | |
- | + | </tr> | |
- | + | </table> | |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
==References== | ==References== |
Revision as of 09:17, 10 December 2010
|
Better Known as: Altace or Ramipro
- Marketed By: King Pharmaceuticals (Now part of Pfizer Inc.)
- Major Indication: Hypertension & Congestive Heart Failure
- Drug Class: ACE Inhibitor
- Date of FDA Approval (Patent Expiration): 1991 (2007)
- 2006 Sales: $650 Million
- Importance: One of the best selling Angiotensin-Converting Enzyme Inhibitors of all time. Long acting ACE Inhibitor.
- See Pharmaceutical Drugs for more information about other drugs and diseases
Mechanism of Action
Angiotensin II has been implicated in cardiac, renal and vascular diseases. [1] Bradykinin, a small peptide that counterbalance the effects of Angiotensin II by acting as a strong vasodilator upon binding AT2, is degraded by the same ACE-1 enzyme. Since ACE-1 is the primary producer of Angiotensin II and degrader of Bradykinins, inhibition of ACE-1 has proven an effective treatment for Hypertension and Congestive Heart Failure. Ramipril is quickly metabolized into Ramiprilat, the most active metabolite of Ramipril. Ramiprilat binds to the active site of , actively inhibiting ACE-1 from binding and converting Angiotensin I into Angiotensin II. ACE-1 using residues Glu 395, His 497, Lys 495, Gln 265, Tyr 504, Tyr 496 and Tyr 507, tightly affixing the inhibitor to the active site of ACE-1.
Pharmacokinetics
For Pharmacokinetic Data References, See: References |
References
- ↑ Ferrario CM. Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst. 2006 Mar;7(1):3-14. PMID:17083068